Table 3.
SARS-CoV-2 Spike specific binding IgG responses in the study population per arm and vaccine type following one dose in those seronegative at baseline.
| n/N | % (95% CI) with serological response* | Difference | Geometric mean concentration | GMT ratio | |
|---|---|---|---|---|---|
| ChadOx1 | |||||
| Standard dose | 11/15 | 73.3 (44.9–92.2) | 4.47(2.81–7.08) | ||
| Half (50%) dose | 12/19 | 63.2 (38.4–83.7) | -10.2 (-39.4–22.2) | 3.27(1.49–7.18) | 0.73 |
| Quarter (25%) dose | 14/22 | 63.6 (40.7–82.8) | -9.7 (-37.6–21.9) | 4.92(2.17–11.15) | 1.50 |
| Ad26.COV2.S | |||||
| Standard dose | 17/27 | 63 (42.4–80.6) | 1.63(2.63–9.93) | ||
| Half (50%) dose | 14/18 | 77.8 (52.4–93.6) | 14.8 (-13.7–39.3) | 1.69(2.16–13.16) | 1.06 |
| Quarter (25%) dose | 10/16 | 62.5 (35.4–84.8) | -0.5 (-30.3–27.7) | 2.67(1.35–5.24) | 0.49 |
| BNT162b2 | |||||
| Standard dose | 19/28 | 67.9 (47.6–84.1) | 1.80(3.31–11.21) | ||
| Half (50%) dose | 18/29 | 62.1 (42.3–79.3) | -5.8 (-29.8–19) | 1.55(2.19–10.12) | 0.77 |
*Defined as increase in IgG above assay threshold.